Hericenones + erinacines — what makes lion's mane unique
Two compound families found nearly nowhere else in nature. One in the fruit body, one in the mycelium. Both shown to induce NGF expression in vitro. Why this matters for product formulation — and where the supplement industry gets it wrong.
The discovery story
Hericium erinaceus (lion's mane) had been used in traditional East Asian medicine for centuries before its bioactive compounds were characterized. The breakthrough came in 1991 when Kawagishi and colleagues isolated a series of novel diterpenoids from the dried fruit body and named them hericenones A through J (Kawagishi et al. 1991, 1992, 1993). Subsequent work isolated a parallel family of cyathane-type diterpenoids from the mycelium and named them erinacines (Kawagishi et al. 1994, 1996).
Both compound families share a common feature: they induce expression of nerve growth factor (NGF) in cultured cells, even at low concentrations. NGF is the protein responsible for neuron survival, differentiation, and growth in the developing and mature nervous system. Compounds that increase NGF expression have been studied extensively as potential treatments for neurodegenerative conditions — though no such treatment has yet been approved.
The discovery was significant because most NGF-inducing compounds known at the time were proteins (NGF itself, BDNF, etc.), which can't cross the blood-brain barrier or be taken orally. Hericenones and erinacines are small lipophilic diterpenoids — exactly the kind of molecule that can potentially reach the brain after oral consumption.
Why fruit body and mycelium are different products
This is the part the supplement industry routinely confuses, and consumers should understand it before buying anything.
Hericenones are concentrated in the fruit body (the visible mushroom). Erinacines are concentrated in the mycelium (the vegetative network underground or on substrate). They are different molecules, with overlapping but distinct activity profiles.
A "lion's mane" product can mean:
- Fruit body extract — high in hericenones, low in erinacines, but contains beta-glucans and proteins that may also matter for immune-side effects.
- Mycelium-on-grain product — usually mostly grain (rice, oats) with mycelium grown into it, dehydrated, and ground. Erinacine content depends heavily on cultivation conditions; bulk grain content can be 40-60% of total mass.
- Pure mycelium extract — rare, expensive, but has the highest erinacine concentration.
- Dual extract — combines fruit body and mycelium for both compound families.
For research purposes, fruit body and dual extract are the most useful — they're what the published clinical trials used (Mori et al. 2009, Saitsu et al. 2019). For consumers, look for products that explicitly state "fruit body" on the label and report the extract:material ratio (8:1 or higher is meaningful; less is often just powder).
What the clinical research actually shows
The most-cited human study is Mori et al. 2009: a 16-week, double-blind, placebo-controlled trial in 30 Japanese adults aged 50-80 with mild cognitive impairment. Subjects took 250 mg of lion's mane powder (yamabushitake) three times daily — total 750 mg/day. Cognitive function (Hasegawa Dementia Scale) improved significantly over the placebo group; the effect dissipated within 4 weeks of stopping.
Saitsu et al. 2019 ran a similar trial in 31 healthy Japanese adults aged 50-80, using 3.2 g/day of lion's mane fruit body for 12 weeks. Working memory and visuospatial reasoning showed measurable improvement vs placebo.
These are small studies. They don't constitute proof that lion's mane "improves cognition" in healthy adults broadly. They do constitute reasonable evidence that the documented compound activity (NGF induction in vitro) translates into measurable functional change in vivo — at meaningful doses, over multi-week timeframes.
Important caveats:
- Clinical doses are 1-3 g/day of fruit body powder, not the 250-500 mg some supplements offer
- Effects appear gradually over weeks, not acutely
- No peer-reviewed evidence for the "instant focus" claims that pepper supplement marketing
- The effect appears reversible — stopping use removes the benefit within 4 weeks
Buying a lion's mane product
Look for fruit body, not mycelium-on-grain. A label that says "Hericium erinaceus mycelium grown on oats" without separating the mycelium from the substrate is mostly oats. Real fruit body products say "fruit body" explicitly.
Look for extract ratios. "8:1 fruit body extract" means 8 grams of dried fruit body were concentrated to 1 gram of extract — the active compounds are 8x more concentrated. "1:1 powder" is just dried mushroom.
Look for beta-glucan content. Beta-glucans are the immunomodulatory polysaccharides in mushroom cell walls. Reputable manufacturers test for them and report a percentage. Sub-15% beta-glucan content suggests heavy substrate inclusion.
Dose to clinical levels. If a product offers 250 mg per capsule, you need 4-6 capsules per day to reach research-grade dosing. Cheaper products that claim sub-clinical doses are not equivalent.
References
- [1] Kawagishi, H. et al. (1991). Hericenones C, D, E, stimulators of nerve growth factor synthesis from the mushroom Hericium erinaceus. Tetrahedron Letters, 32(35), 4561-4564.
- [2] Kawagishi, H. et al. (1994). Erinacines A, B, C, strong stimulators of nerve growth factor synthesis from the mycelia of Hericium erinaceum. Tetrahedron Letters, 35(10), 1569-1572.
- [3] Mori, K. et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367-372.
- [4] Saitsu, Y. et al. (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research, 40(4), 125-131.
- [5] Lai, P-L. et al. (2013). Neurotrophic properties of the lion's mane medicinal mushroom Hericium erinaceus from Malaysia. International Journal of Medicinal Mushrooms, 15(6), 539-554.
Read next
CBD vs CBDA — why the molecular form matters
Most CBD products are sold as CBD. The hemp plant doesn't make CBD — it makes CBDA, which decarboxylates to CBD when heated. Understanding the difference matters for dose, absorption, and what the published research actually measured.
Beta-glucans, dectin-1, and the actual immunology of medicinal mushrooms
The vague claim 'mushrooms boost the immune system' has actual receptor-level mechanism behind it. Beta-glucans bind to dectin-1 on macrophages, triggering measurable immune cascades. Here's the science, and how to read product labels with that knowledge.
The psychedelic legal landscape — where things stand in 2026
Psilocybin, MDMA, ketamine, and related compounds occupy a fragmented legal space — federally Schedule I, but with state-level decriminalization, FDA Breakthrough Designation, and active clinical trials. Here's the actual current state of regulation, and what's hypothetically next.
5,000 years of mushroom medicine — a brief, accurate history
Reishi (Ganoderma) was documented in the Shennong Ben Cao Jing (28-220 CE). The Ötzi the Iceman (5,300 years ago) carried birch polypore. The historical record is much deeper than the recent 'functional mushroom' boom suggests — and the science is finally catching up to what traditional medicine systems had already mapped out.